These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24969795)

  • 41. [Evaluation of the effect of transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with magnetic resonance diffusion-weighted imaging: 4-6-week follow-up of 25 cases].
    Fan WJ; Zhang L; Ouyang YS
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2474-7. PubMed ID: 19080627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
    BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol.
    Schelhorn J; Best J; Reinboldt MP; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
    J Vasc Interv Radiol; 2015 Jul; 26(7):972-9. PubMed ID: 25937296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
    Zhao XT; Li WX; Chai WM; Chen KM
    J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
    Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of hepatocellular carcinoma using apparent diffusion coefficient and diffusion kurtosis indices: preliminary experience in fresh liver explants.
    Rosenkrantz AB; Sigmund EE; Winnick A; Niver BE; Spieler B; Morgan GR; Hajdu CH
    Magn Reson Imaging; 2012 Dec; 30(10):1534-40. PubMed ID: 22819175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
    Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
    AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
    [No Abstract]   [Full Text] [Related]  

  • 49. Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging.
    Suh YJ; Kim MJ; Choi JY; Park MS; Kim KW
    Liver Transpl; 2012 Oct; 18(10):1171-8. PubMed ID: 22767394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
    Birlik B; Obuz F; Elibol FD; Celik AO; Sokmen S; Terzi C; Sagol O; Sarioglu S; Gorken I; Oztop I
    Magn Reson Imaging; 2015 Feb; 33(2):201-12. PubMed ID: 25460330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis.
    Agnello F; Ronot M; Valla DC; Sinkus R; Van Beers BE; Vilgrain V
    Radiology; 2012 Feb; 262(2):511-9. PubMed ID: 22143926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q; Li A; Sun S; Luo R; Chen F
    J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Free-Breathing With Navigator-Triggered Technique in Diffusion Weighted Imaging for Evaluation of Small Hepatocellular Carcinoma: Effect on Image Quality and Intravoxel Incoherent Motion Parameters.
    Shan Y; Zeng MS; Liu K; Miao XY; Lin J; Fu Cx; Xu PJ
    J Comput Assist Tomogr; 2015; 39(5):709-15. PubMed ID: 26196345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of Liver Tumors by Diffusion-Weighted Imaging: Comparison of Diagnostic Performance Using the Mean and Minimum Apparent Diffusion Coefficient.
    Namimoto T; Nakagawa M; Kizaki Y; Itatani R; Kidoh M; Utsunomiya D; Oda S; Yamashita Y
    J Comput Assist Tomogr; 2015; 39(4):453-61. PubMed ID: 25836022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The usefulness of diffusion-weighted imaging in the characterization of liver lesions in patients with cirrhosis.
    Sandrasegaran K; Tahir B; Patel A; Ramaswamy R; Bertrand K; Akisik FM; Saxena R
    Clin Radiol; 2013 Jul; 68(7):708-15. PubMed ID: 23510619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
    Buijs M; Kamel IR; Vossen JA; Georgiades CS; Hong K; Geschwind JF
    J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The value of liver and spleen ADC measurements in the diagnosis and follow up of hepatic fibrosis in chronic liver disease.
    Tokgöz Ö; Unal I; Turgut GG; Yildiz S
    Acta Clin Belg; 2014 Dec; 69(6):426-32. PubMed ID: 25103596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does diffusion-weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd-EOB-DTPA with and without DWI.
    Schelhorn J; Best J; Reinboldt MP; Dechêne A; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
    J Magn Reson Imaging; 2015 Sep; 42(3):818-27. PubMed ID: 25515676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization.
    Deng J; Miller FH; Rhee TK; Sato KT; Mulcahy MF; Kulik LM; Salem R; Omary RA; Larson AC
    J Vasc Interv Radiol; 2006 Jul; 17(7):1195-200. PubMed ID: 16868174
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatocellular carcinoma: short-term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T.
    Kakite S; Dyvorne H; Besa C; Cooper N; Facciuto M; Donnerhack C; Taouli B
    J Magn Reson Imaging; 2015 Jan; 41(1):149-56. PubMed ID: 24415565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.